Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: Focus on methylphenidate formulations

Pharmacotherapy

Volumn 23, Issue 10 II, 2003, Pages 1281-1299

  Markowitz, John S ^a,c   Straughn, Arthur B ^b   Patrick, Kennerly S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; FLUOXETINE; GUANFACINE; IMIPRAMINE; METHYLPHENIDATE; NORADRENALIN UPTAKE INHIBITOR; PEMOLINE; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

APPETITE DISORDER; AREA UNDER THE CURVE; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CHILD PSYCHIATRY; DOPAMINERGIC SYSTEM; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG RELEASE; DRUG STRUCTURE; FOOD DRUG INTERACTION; HUMAN; LIVER TOXICITY; NEUROPATHOLOGY; PSYCHOSOCIAL CARE; REVIEW; SLEEP DISORDER;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DELAYED-ACTION PREPARATIONS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METHYLPHENIDATE; RANDOMIZED CONTROLLED TRIALS; SEX FACTORS; TREATMENT OUTCOME;

EID: 0141865635     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.12.1281.32697     Document Type: Review

References (146)

1. Swanson JM, Seargent JA, Taylor E, Sonuga-Barke EJS, Jensen PS, Cantwell DP. Attention deficit disorder and hyperkinetic disorder. Lancet 1998;351:429-33.
2. Dulcan M, for the Work Group on Quality Issues. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997;36: S85-121.
3. Homer CJ, Baltz RD, Hickson GB, et al. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics 2000;105:1158-70.
4. Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit-hyperactivity disorder. N Engl J Med 1999;340:780-8.
5. Goldman LS, Genel M, Bezman RJ, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 1998;279:1100-7.
6. Robison LM, Skaer TL, Sclar DA, Galin RS. Is attention deficit hyperactivity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants. CNS Drugs 2002;16:129-37.
7. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1073-86.
8. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry 1998;155:493-8.
9. Weiss M, Murray C. Assessment and management of attention-deficit hyperactivity disorder in adults. Can Med Assoc J 2003;168:715-22.
10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000.
11. Tannock R. Attention deficit hyperactivity disorder: advances in cognitive, neurobiological, and genetic research. J Child Psychol Psychiatry 1998;39:65-99.
12. Spencer T, Biederman J, Wilens T. Attention-deficit/hyperactivity disorder and comorbidity. Pediatr Clin North Am 1999;46:915-27.
13. DiScala C, Lescohier I, Barthel M, Li G. Injuries to children with attention deficit hyperactivity disorder. Pediatrics 1998;102:1415-21.
14. Milberger S, Biederman J, Faraone SV, Chen L, Jones J. ADHD is associated with early initiation of cigarette smoking in children and adolescents. Am Acad Child Adolesc Psychiatry 1997;36:37-44.
15. Biederman J, Wilens T, Mick E, Spencer T, Faraone SV. Pharmacotherapy of attention deficit/hyperactivity disorder reduces risk for substance use disorder [online exclusive article]. Pediatrics 1999;104:e20-4. Available from http://pediatrics.aappublications.org. Accessed May 18, 2002.
16. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003;111:179-85.
17. Leibson CL, Katusic SK, Barbaresi WJ, Ransom J, O'Brien PC. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA 2001;285:60-6.
18. Chan E, Zhan CL, Homer CJ. Health care use costs for children with attention-deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey Arch Pediatr Adolesc Med 2002;156:504-11.
19. Kirley A, Hawi Z, Phil M, et al. Dopaminergic system genes in ADHD: toward a biological hypothesis. Neuropsychopharmacology 2002;27:607-19.
20. Winsberg BG, Comings DE. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry 1999;38: 1474-7.
21. Wigg K, Zai G, Schachar R, et al. Attention deficit hyperactivity disorder and the gene for dopamine beta-hydroxylase. Am J Psychiatry 2002;159:1046-8.
22. Silver LB. Alternative (nonstimulant) medications in the treatment of attention-deficit/hyperactivity disorder in children. Pediatr Clin North Am 1999;46:965-75.
23. 2-Adrenergic agonists: neurochemistry, efficacy, and clinical guidelines for use in children. Pediatr Clin North Am 1998;45:1099-122.
24. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002;41:776-84.
25. National Institutes of Health Consensus Development Program. Diagnosis and treatment of attention deficit hyperactivity disorder. NIH consensus statement Nov 16-18, 1998;16(2):1-37. Available from http://odp.od.nih.gov/consensus/cons/110/110_statement.htm. Accessed March 25, 2003.
26. Zametkin AJ, Ernst M. Problems in the management of attention-deficit-hyperactivity disorder. N Engl J Med 1999;340:40-6.
27. American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:1033-44.
28. Madras BK, Miller GM, Fischman AJ. The dopamine transporter: relevance to attention deficit hyperactivity disorder (ADHD). Behav Brain Res 2002;130:57-63.
29. Greenhill LL, Pliszka S, Dulcan MK, and the Work Group on Quality Issues: AACAP. Practice parameters for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41(suppl 2):S26-49.
30. Centers for Disease Control and Prevention. Attention deficit disorder and learning disability: United States, 1997-98. Vital and health statistics, series 10, no. 206. Atlanta, GA: Centers for Disease Control and Prevention, May 2002.
31. James RS, Sharp WS, Bastain TM, et al. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J Am Acad Child Adolesc Psychiatry 2001;40:1268-76.
32. Manos MJ, Short EJ, Findling RL. Differential effectiveness of methylphenidate and Adderall in school-age youths with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999;38:813-19.
33. Pliszka SR, Brown R, Olvera RL, Wynne SK. A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2000;39:619-26.
34. Faraone SV, Biederman J, Roe C. Comparative efficacy of Adderall and methylphenidate in attention deficit/hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol 2002;22:468-73.
35. Zabik JE, Levin RM, Maickel RP. Drug interaction with brain biogenic amines and the effects of amphetamine isomers on locomotor activity. Pharmacol Biochem Behav 1978;8:429-35.
36. Arnold LE, Huestis RD, Smeltzer DJ, et al. Levamphetamine vs dextroamphetamine in minimal brain dysfunction. Arch Gen Psychiatry 1976;33:292-301.
37. Greenhill LL, Halperin JM, Abikoff H. Stimulant medications. J Am Acad Child Adolesc Psychiatry 1999;38:503-12.
38. Faraone SV, Short EJ, Biederman J, Findling RL, Roe C, Manos MJ. Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a drug-placebo and drug-drug response curve analysis of a naturalistic study. Int Neuropsychopharmacol 2002;5:121-9.
39. Pelham WE, Aronoff HR, Midlam JK, et al. A comparison of Ritalin and Adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder [online exclusive articlel. Pediatrics 1999;103:e43. Available from http://pediatrics.aappublications.org. Accessed April 20, 2001.
40. Pliszka SR, Greenhill LL, Crismon ML, et al. The Texas children's medication algorithm project: report of the Texas consensus conference panel on medication treatment of childhood attention-deficit/hyperactivity disorder. I. Attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2000;39:908-19.
41. Arnold LE. Methylphenidate vs amphetamine: comparative review. J Attent Disord 2000;3:200-11.
42. Stein MA, Blondis TA, Schnitzer ER, et al. Methylphenidate dosing: twice daily versus three times daily. Pediatrics 1996;98:748-56.
43. Andriola MR. Efficacy and safety of methylphenidate and pemoline in children with attention deficit hyperactivity disorder. Curr Ther Res Clin Exp 2000;61:208-15.
44. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity across the life cycle. J Am Acad Child Adolesc Psychiatry 1996;35:409-32.
45. Heil SH, Holes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug abusers. Drug Alcohol Depend 2002;67:149-56.
46. Glase SA, Robertson DW, Wise LD. Attention deficit disorder: pathophysiology and design of new treatments. Annu Rep Med Chem 2002;37:11-20.
47. Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996;35:1314-21.
48. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001;158:1067-74.
49. Volkow ND, Wang G-J, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998;155:1325-31.
50. Volkow ND, Wang G-J, Fowler JS, et al. Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci 1999;65:7-12.
51. Volkow ND, Wang G-J, Fowler JS, et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 2002;48:181-7.
52. Ruskin DN, Berstrom DA, Shenker A, Freeman LE, Back D, Walters JR. Drugs used in the treatment of attention-deficit/hyperactive disorder affect postsynaptic firing rate and oscillation without preferential dopamine autoreceptor action. Biol Psychiatry 2001;49:340-50.
53. Volkow ND, Wang GJ, Fowler JS, et al. "Nonhedonic" food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. Synapse 2002;44:175-80.
54. Seeman P, Madras BK. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry 1998;3:386-96.
55. Hitri A, Hurd YL, Wyatt RJ, et al. Molecular, functional and biochemical characteristics of the dopamine transporter: regional differences and clinical relevance. J Clin Neuropharmacol 1994;17:1-22.
56. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998;94:127-52.
57. Seeman P, Madras B. Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: a hypothesis. Behav Brain Res 2002;130:79-83.
58. Patrick KS, Markowitz JS. Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder: a review. Hum Psychopharmacol 1997;12:527-46.
59. Patrick KS, Caldwell RW, Ferris RM, et al. Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther 1987;241:152-8.
60. Heron C, Costentin J, Bonnet JJ. Evidence that pure uptake inhibitors including cocaine interact slowly with the dopamine neuronal carrier. Eur J Pharmacol 1994;264: 391-8.
61. Szporny L, Gorog P. Investigations into the correlations between monoamine oxidase and other effects due to methylphenidate and its isomers. Biochem Pharmacol 1961;8:263-8.
62. Rometsch R. Process for the conversion of stereoisomers. U.S. patent 2,838,519. June 10, 1958.
63. Srinivas NR, Hubbard JW, Quinn D, et al. Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin Pharmacol Ther 1992;52:561-8.
64. Aoyama T, Sasaki T, Kotaki J. Pharmacokinetics and pharmacodynamics of (+)-threo-methylphenidate enantiomer in patients with hypersomnia. Clin Pharmacol Ther 1994;55:270-6.
65. Srinivas NR, Hubbard JW, Korchinski ED, et al. Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans. Pharm Res 1993;10:14-21
66. Findling RL, Short E, Manos MJ. Short-term cardiovascular effects of methylphenidate and Adderall. J Am Acad Child Adolesc Psychiatry 2001;40:525-9.
67. Stowe CD, Gardner SF, Gist CC, Schulz EG, Wells TG. 24-Hour ambulatory blood pressure monitoring in male children receiving stimulant therapy. Pediatrics 2002;36:1142-9.
68. Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit disorder: a double-blind, crossover trial. Pediatrics 1997;100:662-6.
69. Eckerman DA, Moy SS, Perkins AN, et al. Enantioselective behavioral effects of threo methylphenidate in rats. Pharmacol Biochem Behav 1991;40:875-80.
70. Rouhi AM. Chirality at work. Chem Engin News 2003;May 4:56-61.
71. Davids E, Zhang K, Tarazi FI, Baldessarini RJ. Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. Psychopharmacology 2002;160:92-8.
72. Teo SK, Stirling DI, Thomas SD, Khetani VD. Neurobehavioral effects of racemic threo-methylphenidate and its D and L enantiomers in rats. Pharmacol Biochem Behav 2003;74:747-54.
73. Teo S, Stirling D, Thomas S, Hoberman A, Kiopes A, Khetani V. A 90-day oral gavage toxicity study of D-methylphenidate and D, L-methylphenidate in Sprague-Dawley rats. Toxicology 2002;179:183-96.
74. Patrick KS, Kilts CD, Breese GR. Synthesis and pharmacology of hydroxylated metabolites of methylphenidate. J Med Chem 1981;29:1237-40.
75. Bartlett MF, Egger HP. Disposition and metabolism of methylphenidate in dog and man. Fed Proc 1972;31:537.
76. 14C: studies in man and animals. J Pharmacol Exp Ther 1974;191:535-47
77. Redalieu E, Bartlett MF, Waldes LM, et al. A study of methylphenidate in man with respect to its major metabolite. Drug Metab Dispos 1982;10:708-9.
78. Chan YP, Swanson JM, Soldin SS, et al. Methylphenidate hydrochloride given with or before breakfast. II. Effects on plasma concentration of methylphenidate and ritalinic acid. Pediatrics 1983;72:56-9
79. Wargin W, Patrick K, Kilts C, et al. Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther 1983;226:382-6.
80. Modi NB, Lindemulder G, Gupta SK. Single- and multipledose pharmacokinetics of oral once-a-day osmotic controlled-release OROS™ (methylphenidate HCl) formulation. J Clin Pharmacol 2000;40:379-88.
81. Modi NB, Wang B, Hu WT, Gupta SK. Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects. Biopharm Drug Dispos 2000;21:23-31.
82. Modi NB, Wang B, Noveck RJ, et al. Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic controlled-release oral delivery system. J Clin Pharmacol 2000;40:1141-9.
83. Bosron WF, Hurley TD. Lessons from a bacterial cocaine esterase. Nat Struct Biol 2002;9:4-5.
84. Jonkman LM, Verbaten MN, deBoer D, et al. Differences in plasma concentrations of the D- and L-threo methylphenidate enantiomers in responding and non-responding children with attention-deficit hyperactivity disorder. Psychiatry Res 1998;78:115-18.
85. Ding YS, Fowler JS, Volkow ND. Is the l-threo enantiomer of methylphenidate (Ritalin) inactive in the brain when given orally? Presented at the 41st annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, Dec 8-12, 2002.
86. Patrick KS, Ellington KR, Breese GR, et al. Gas chromatographic-mass spectrometric analysis of methylphenidate and p-hydroxy-methylphenidate using deuterated internal standards. J Chromatogr B Biomed Appl 1985;343:329-38.
87. DeVane CL, Markowitz JS, Carson SW, et al. Single dose methylphenidate pharmacokinetics in CYP 2D6 extensive and poor metabolizers. J Clin Psychopharmacol 2000;20:347-9.
88. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003;42:59-98.
89. Markowitz JS, Morrison SD, DeVane CL. Drug interactions with psychostimulants. Int Clin Psychopharmacol 1999;14:1-18.
90. Markowitz JS, Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet 2001;40:753-72.
91. Remich SA, Desta Z, Soukhova NV, Flockhart DA. In vitro inhibition of cytochrome P450s by ephedrine, methylphenidate and its main metabolite ritalinic acid [abstr]. Clin Pharmacol Ther 2002;71:P60.
92. DeVane CL, Wang JS, Pennick M, et al. Effects of amphetamine and methylphenidate on cytochrome P450 activity. Poster presentation at the 156th annual meeting of the American Psychiatric Association, San Francisco, CA, May 19, 2003.
93. Markowitz JS, Logan BK, Diamond F, et al. Detection of the novel metabolite ethylphenidate following methylphenidate overdose with alcohol co-ingestion. J Clin Psychopharmacol 1999;19:362-6.
94. Markowitz JS, DeVane CL, Boulton DW, et al. Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and alcohol. Drug Metab Dispos 2000;25:620-4.
95. Satoh T, Hosokawa M. The mammalian carboxyesterases: from molecules to function. Annu Rev Pharmacol Toxicol 1998;38:257-88.
96. Roberts SM, Harbison RD, James RC. Inhibition by ethanol of the metabolism of cocaine to benzoylecgonine and ecgonine methyl ester in mouse and human liver. Drug Metab Dispos 1993;21:537-41.
97. Thomson MR, Dowd JJ, Markowitz JS, DeVane CL, Patrick KS. Enantioselective transesterification of methylphenidate to ethylphenidate after coadministration with ethanol [abstr]. J Clin Pharmacol 2002;42:1069.
98. Hungund BL, Perel JM, Hurwic MJ, Sverd J, Winsberg BG. Pharmacokinetics of methylphenidate in hyperkinetic children. Br J Clin Pharmacol 1979;8:571-6.
99. Chan YPM, Soldin SJ, Swanson JM, et al. Gas chromatographic/mass spectrometric analysis of methylphenidate (Ritalin) in serum. Clin Biochem 1980;13:266-72.
100. Shaywitz SE, Hunt RD, Jatlow P, et al. Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine, and behavioral measures following acute chronic treatment with methylphenidate. Pediatrics 1982;69:688-94.
101. Birmaher B, Greenhill LL, Cooper TB, Fried J, Maminski B. Sustained release methylphenidate: pharmacokinetic studies in ADHD males. J Am Acad Child Adolesc Psychiatry 1989;28:768-72.
102. Patrick KS, Straughn AB, Jarvi EJ, Breese GR, Meyer MC. The absorption of sustained-release methylphenidate formulation compared to an immediate-release formulation. Biopharm Drug Dispos 1989;10:165-71.
103. Lies HJ, Fauler G, Rasotnig G, Windischhofer. Negative ion chemical ionization for the determination of methylphenidate in human plasma by stable isotope dilution gas chromatography/mass spectrometry. J Mass Spectrom 2000;35:1100-4.
104. Meyer MC, Straughn AB, Jarvi EJ, et al. Bioequivalence of methylphenidate immediate-release tablets using a replicated study design to characterize intrasubject variability. Pharm Res 2000;17:381-4.
105. Gonzalez MA, Pentikis HS, Anderi N, et al. Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 2002;40:175-84.
106. Pentikis HS, Simmons RD, Benedict MF, Hatch SJ. Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered on food or as an intact capsule. J Am Acad Child Adolesc Psychiatry 2002;41:443-9.
107. Markowitz JS, Straughn AB, Patrick KS, et al. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet 2003;42:393-401.
108. Wigal SB, Sanchez DY, DeCory HH, D'Imperio JM, Swanson JM. Selection of the optimal dose ratio for a controlled-delivery formulation of methylphenidate. J Appl Res 2003;3:46-63.
109. Lim HK, Hubbard J, Midha KK. Development of enantioselective gas chromatographic quantitation assay for dl-threo-methylphenidate in biological fluids. J Chromatogr 1986;378:109-23.
110. Srinivas NR, Quinn D, Hubbard JW, Midha KK. Stereoselective disposition of methylphenidate in children with attention-deficit disorder. J Pharmacol Exp Ther 1987;241:300-6.
111. Hubbard JW, Srinivas NR, Quinn D, Midha KK. Enantioselective aspects of the disposition of all dl-threo-methylphenidate after the administration of a sustained-release formulation to children with attention deficit-hyperactivity disorder. J Pharma Sci 1989;78:944-7.
112. Aoyama T, Kotataki H, Honda Y, Nakagawa F. Kinetic analysis of enantiomers of threo-methylphenidate and its metabolite in two healthy subjects after oral administration as determined by a gas chromatographic-mass spectrometric method. J Pharm Sci 1990;79:465-9.
113. Srinivas NR, Hubbard JW, Midha KK. Enantioselective gas chromatographic assay with electron-capture detection of dl-ritalinic acid in plasma. J Chromatogr B 1990;530:327-36.
114. Aoyama T, Kotaki J, Sasaki T, Sawada Y, Honda Y, Iga T. Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers. Eur J Clin Pharmacol 1993;44:79-84.
115. Srinivas NR, Hubbard JW, Korchinski ED, et al. Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans. Pharm Res 1993;286:880-1.
116. Ramos L, Bakhtiar K, Majumdar T, et al. Liquid chromatography/ atmospheric pressure chemical ionization tandem mass spectrometry enantiomeric separation of dl-threo-methylphenidate (Ritalin®), using a macrocyclic antibiotic as the chiral selector. Rapid Commun Mass Spectrom 1999;13:2054-62.
117. Midha KK, McKay G, Rawson MJ, Korchinski ED, Hubbard JW. Effects of food on the pharmacokinetics of methylphenidate. Pharmaceut Res 2001;18:1185-9.
118. Teo S, Scheffler D, Stirling D, Thomas V, Khetani V. A single-dose, 2-way crossover, bioequivalence study of dexmethylphenidate with and without food in healthy subjects [abstr]. Clin Pharmacol Ther 2003;PII:28.
119. Food and Drug Administration. Concerta (methylphenidate HCl) extended-release tablets. Company: Alza Corporation. Application no.:21-121. Available from http://www.fda.gov/cder/approval/index. Accessed April 15, 2003.
120. Shader RI, Harmatz JS, Osterheld JR, Parmalee DX, Sallee FR, Greenblatt DJ. Population pharmacokinetics of methylphenidate in children with attention-deficit hyperactivity disorder. J Clin Pharmacol 1999;39:775-85.
121. Auiler JF, Lui K, Lynch JM, Gelotte CK. Effect of food on the early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR food evaluation (CAFÉ) study. Curr Med Res Opin 2002;18:311-16.
122. Wong NY, King SP, Laughton WB, et al. Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers. J Clin Pharmacol 1998;38:276-82.
123. Novartis Pharmaceuticals Corporation. Data on file. East Hanover, NJ; 2003.
124. Keating GM, Figgitt DP. Dexmethylphenidate. Drugs 2002;62:1899-1904.
125. Markowitz JS, Straughn AB, Patrick KS, et al. Comparative pharmacokinetics of two long-acting methylphenidate formulations: analysis of sex differences and treatment implications. Poster presentation at the 43rd annual meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, May 29, 2003.
126. Committee on Children with Disabilities and Committee on Drugs. Medication for children with attentional disorders. Pediatrics 1996;98:301-4.
127. Kollins SH, Rush CR, Pazzaglia PJ, Ali JA. Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exper Clin Psychopharmacol 1998;6:367-74.
128. Pelham WE, Greenslade KE, Vodde-Hamilton M, et al. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 1990;86:226-37.
129. Swanson J, Kinsbourne M, Roberts W, Zucker K. Time-response analysis of the effect of stimulant medication on the learning ability of children referred for hyperactivity. Pediatrics 1978;61:21-9.
130. Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 2003;60:204-11.
131. Greenhill LL. Pharmacologic treatment of attention deficit hyperactivity disorder. Psychiatr Clin North Am 1992;15:1-27.
132. Swanson J, Gupta S, Guinta D, et al. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther 1999;66:295-305.
133. Swanson JM, Volkow ND. Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD. Behav Brain Res 2002;130:73-8.
134. Swanson JM, Gupta S, Williams L, Agler D, Lerner M, Wigal S. Efficacy of a new pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity level in the classroom and on the playground. J Am Acad Child Adolesc Psychiatry 2002;41:1306-14.
135. Alza Corporation. Concerta (methylphenidate HCl) package insert. Mountain View, CA; 2000.
136. Lyseng-Williamson KA, Keating GM. Extended-release methylphenidate (Ritalin LA). Drugs 2002;62:2251-9.
137. Wagner MW, Markowitz JS, Patrick KS. Methylphenidate ER lodging in esophagus [letter]. J Am Acad Child Adolesc Psychiatry 2001;40:1244-5.
138. Jaffe SL. Failed attempt at intranasal abuse of Concerta [letter]. J Am Acad Child Adolesc Psychiatry 2002;41:5.
139. Lee L, Kepple J, Wang Y, et al. Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce. Biopharm Drug Dispos 2003;24:233-43.
140. Food and Drug Administration, Center for Drug Evaluation and Research. Approved drug products with therapeutic equivalence ratings. Available from http://www.fda.gov/cder/ob/docs/preface/ectablec.htm. Accessed March 24, 2003.
141. Greenhill LL, DeCory HH, Hirshey Dirksen SJ, Hatch SJ. Comparison of classroom deportment in 6-12 year olds with ADHD after administration of two once-daily extended release methylphenidate (MPH) formulations. Poster presentation at the 156th annual meeting of the American Psychiatric Association, San Francisco, CA, May 21, 2003.
142. Lopez FA, Silva RR, Pestreich L, Muniz R. Comparative efficacy of two long-acting formulations of methylphenidate (Ritalin LA and Concerta) and placebo in a simulated classroom setting. Poster presentation at the 43rd annual meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, May 29, 2003.
143. Dring YS, Fowler JS, Volkow ND, et al. Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and l-threo-methylphenidate in the human and baboon brain. Psychopharmacology 1997;131:71-8.
144. Srinivas NR, Barbhaiya RH, Midha KK. Enantiomeric drug development: issues, considerations, and regulatory requirements. J Pharm Sci 2001;90:1205-15.
145. Novartis Pharmaceuticals Corporation. Focalin (dexmethylphenidate HCl) package insert. East Hanover, NJ; 2001.
146. Scheffler MR, Teo S, Stirling D, Thomas S, Khetani AV. Multiple dosing of dexmethylphenidate HCL (D-MPH) does not result in accumulation or interconversion to L-methylphenidate HCL in male and female children [abstr]. Clin Pharmacol Ther 2003;PII:27.